BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Clinical & Diagnostic

HKeyBio Launches NHP Fast-Tox Program to Accelerate Early Safety Assessment for Biologics

The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics an...

June 26, 2026 | News

Waters and IMU Biosciences Partner to Advance AI-Powered High-Definition Immune Profiling

MU's AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyze...

June 26, 2026 | News

Metabolon Delivers Landmark Metabolomics Dataset to Advance Rare Disease Research with Genomics England

Metabolon, Inc., the global leader in metabolomics solutions advancing life science research, diagnostics, therapeutics, and precision medicine, announced ...

June 26, 2026 | News

HaemaLogiX Secures Ethics Approval For Phase 2b KappaMab Clinical Trial In Relapsed Multiple Myeloma

Ethics approval received from the Alfred Hospital Human Research Ethics Committee (Bayside Health) for Phase 2b KappaMab™ clinical trial “HLX...

June 22, 2026 | News

Gesynta Pharma Reaches 50% Patient Enrollment in Phase II Endometriosis Trial of Vipoglanstat

Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190...

June 18, 2026 | News

Akeso Enrols First Patient in Phase Ib/II Trial of Next-Generation HER3 ADC AK138D1 for Advanced Breast Cancer

Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally...

June 17, 2026 | News

Dimerix Signs Up to AU$481 Million Licensing Deal with Everest Medicines to Advance Phase 3 Kidney Disease Therapy Across Asia

Dimerix Limited (ASX: DXB), a biopharmaceutical company developing innovative therapies for rare inflammatory diseases, has entered into an exclusive licen...

June 17, 2026 | News

QIAGEN Bets Big on Digital PCR with Major QIAcuity Ecosystem Expansion

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology applic...

June 16, 2026 | News

Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data

Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...

June 15, 2026 | News

SK Bioscience Licenses CDC Rotavirus Vaccine Technology to Advance Global Immunisation Efforts

SK bioscience licenses vaccine technology from the U.S. Centers for Disease Control and Prevention SK bioscience is jointly investing with t...

June 11, 2026 | News

Harbour BioMed Secures China IND Acceptance for Novel Bispecific Cancer Therapy HBM7004

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

June 12, 2026 | News

Everest Medicines Strengthens Asia Pacific Growth Strategy With Sumecigrel Licensing Agreement

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

June 10, 2026 | News

OriCell Advances First GPC3 CAR T Therapy Into Confirmatory Phase II Trial for Advanced Liver Cancer

OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") , announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101,...

June 08, 2026 | News

Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immun...

June 04, 2026 | News

Stay Connected